These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 18713838)

  • 1. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism.
    Lee YH; Albig AR; Regner M; Schiemann BJ; Schiemann WP
    Carcinogenesis; 2008 Dec; 29(12):2243-51. PubMed ID: 18713838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.
    Taylor MA; Parvani JG; Schiemann WP
    J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):169-90. PubMed ID: 20467795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.
    Galliher AJ; Schiemann WP
    Breast Cancer Res; 2006; 8(4):R42. PubMed ID: 16859511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
    Sokol JP; Neil JR; Schiemann BJ; Schiemann WP
    Breast Cancer Res; 2005; 7(5):R844-53. PubMed ID: 16168131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.
    Allington TM; Galliher-Beckley AJ; Schiemann WP
    FASEB J; 2009 Dec; 23(12):4231-43. PubMed ID: 19690215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.
    Neil JR; Johnson KM; Nemenoff RA; Schiemann WP
    Carcinogenesis; 2008 Nov; 29(11):2227-35. PubMed ID: 18725385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells.
    Taylor MA; Amin JD; Kirschmann DA; Schiemann WP
    Neoplasia; 2011 May; 13(5):406-18. PubMed ID: 21532881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noncanonical TGF-β signaling during mammary tumorigenesis.
    Parvani JG; Taylor MA; Schiemann WP
    J Mammary Gland Biol Neoplasia; 2011 Jun; 16(2):127-46. PubMed ID: 21448580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia.
    Richards EJ; Zhang G; Li ZP; Permuth-Wey J; Challa S; Li Y; Kong W; Dan S; Bui MM; Coppola D; Mao WM; Sellers TA; Cheng JQ
    J Biol Chem; 2015 Mar; 290(11):6857-67. PubMed ID: 25605728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer.
    Juang YL; Jeng YM; Chen CL; Lien HC
    Mol Carcinog; 2016 Dec; 55(12):2247-2259. PubMed ID: 26824226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.
    Allington TM; Schiemann WP
    Cells Tissues Organs; 2011; 193(1-2):98-113. PubMed ID: 21051857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment.
    Tian H; Liu J; Chen J; Gatza ML; Blobe GC
    Oncogene; 2015 Nov; 34(45):5635-47. PubMed ID: 25823021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
    Wendt MK; Schiemann WP
    Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
    Wendt MK; Smith JA; Schiemann WP
    Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.
    Tian M; Schiemann WP
    FASEB J; 2010 Apr; 24(4):1105-16. PubMed ID: 19897661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
    Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
    Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
    Galliher-Beckley AJ; Schiemann WP
    Carcinogenesis; 2008 Feb; 29(2):244-51. PubMed ID: 18174260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.
    Lenferink AE; Cantin C; Nantel A; Wang E; Durocher Y; Banville M; Paul-Roc B; Marcil A; Wilson MR; O'Connor-McCourt MD
    Oncogene; 2010 Feb; 29(6):831-44. PubMed ID: 19935703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.
    Johansson J; Berg T; Kurzejamska E; Pang MF; Tabor V; Jansson M; Roswall P; Pietras K; Sund M; Religa P; Fuxe J
    Oncogene; 2013 Dec; 32(50):5614-24. PubMed ID: 23955085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.
    Huber MA; Azoitei N; Baumann B; Grünert S; Sommer A; Pehamberger H; Kraut N; Beug H; Wirth T
    J Clin Invest; 2004 Aug; 114(4):569-81. PubMed ID: 15314694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.